Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 4/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3720050 | 0.89 | POLB (0.60) | KHKPOLBLMNATHRBMEN1 | |
| SCHEMBL4940990 | 0.84 | USP30 (0.56) | POLBLMNATHRBDGAT2HDAC4 | |
| SCHEMBL3724794 | 0.84 | USP30 (0.56) | POLBLMNATHRBDGAT2HDAC4 | |
| SCHEMBL22358112 | 0.82 | HDAC4 (0.54) | POLBLMNATHRBMEN1KMT2A | |
| SCHEMBL31279611 | 0.80 | KHK (1.00) | KHKHPGDS | |
| SCHEMBL23711737 | 0.80 | KHK (1.00) | KHKHPGDS | |
| SCHEMBL13199301 | 0.79 | KDM4E (0.68) | POLBLMNATHRBMEN1KMT2A | |
| SCHEMBL3668808 | 0.78 | LMNA (0.49) | POLBLMNATHRBMEN1KMT2A | |
| SCHEMBL7756336 | 0.78 | HDAC4 (0.51) | POLBLMNATHRBMEN1KMT2A | |
| SCHEMBL3720046 | 0.77 | ALDH1A1 (0.58) | POLBLMNATHRBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2021-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11083720-B2 | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases | KHK, GCK, HK1 | KHK 1/4885POLB 4241/4885LMNA 4468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.